Literature DB >> 26153639

A precision, personalized approach to the management of bladder cancer.

Andrea B Apolo1, Maximilian Burger.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26153639      PMCID: PMC6777553          DOI: 10.1097/MOU.0000000000000195

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


× No keyword cloud information.
  2 in total

1.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Authors:  Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

2.  Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

Authors:  J-B Cazier; S R Rao; C M McLean; A K Walker; A L Walker; B J Wright; E E M Jaeger; C Kartsonaki; L Marsden; C Yau; C Camps; P Kaisaki; J Taylor; J W Catto; I P M Tomlinson; A E Kiltie; F C Hamdy
Journal:  Nat Commun       Date:  2014-04-29       Impact factor: 14.919

  2 in total
  2 in total

Review 1.  Precision oncology in urothelial cancer.

Authors:  Elizabeth Liow; Ben Tran
Journal:  ESMO Open       Date:  2020-03

Review 2.  Current status and future perspectives of immunotherapy in bladder cancer treatment.

Authors:  Zhangsong Wu; Jinjian Liu; Ruixiang Dai; Song Wu
Journal:  Sci China Life Sci       Date:  2020-08-26       Impact factor: 6.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.